NCT04227015

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: He Huang · Academic / Other
• Sex: All
• Age: 3 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy

Detailed description

This is a single arm, open-label, single-center study. This study is indicated for relapsed or refractory CD19+ B-line hematological malignancy: B-ALL and B-NHL. the selection of dose levels and the number of subjects are based on clinical tiral of similar foreign products. 2 groups of patients will be enrolled, 36 in each group. Primary objective is to explore the safety, main consideration is dose-related safety.

Conditions

• Acute Lymphoblastic Leukemia
• Non-hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	CTA101	CTA101 UCAR-T cell injection by intravenous infusion

Timeline

• Start date: 2020-01-08
• Primary completion: 2022-01-08
• Completion: 2027-05-31
• First posted: 2020-01-13
• Last updated: 2020-12-28

Locations

1 site across 1 country: China